Table 2. Clinical outcomes according to ESC/EACTS-endorsed HIR features.
| Unadjusted | MV Adjusted ＊ | |||||
|---|---|---|---|---|---|---|
|
HIR ( n = 5149) |
Non-HIR ( n = 5018) | HR (95% CI) | P value | HR (95% CI) | P value | |
| Target vessel failure a | 357 (6.9%) | 219 (4.4%) | 1.62 (1.37-1.91) | ＜0.001 | 1.48 (1.25-1.74) | ＜0.001 |
| Patient-oriented composite outcome b | 677 (13.1%) | 442 (8.8%) | 1.54 (1.36-1.73) | ＜0.001 | 1.44 (1.28-1.63) | ＜0.001 |
| Target lesion failure c | 296 (5.7%) | 174 (3.5%) | 1.68 (1.40-2.03) | ＜0.001 | 1.52 (1.26-1.85) | ＜0.001 |
| All-cause death | 81 (1.6%) | 53 (1.1%) | 1.49 (1.05-2.10) | 0.025 | 1.37 (0.96-1.96) | 0.086 |
| Cardiac death | 50 (1.0%) | 22 (0.4%) | 2.21 (1.34-3.65) | 0.002 | 1.95 (1.16-3.29) | 0.012 |
| Myocardial infarction | 138 (2.7%) | 58 (1.2%) | 2.33 (1.72-3.17) | ＜0.001 | 2.07 (1.51-2.83) | ＜0.001 |
| Target-vessel MI | 63 (1.2%) | 26 (0.5%) | 2.37 (1.50-3.74) | ＜0.001 | 2.08 (1.31-3.32) | 0.002 |
| Definite/probable ST | 52 (1.0%) | 19 (0.4%) | 2.67 (1.58-4.52) | ＜0.001 | 2.48 (1.45-4.24) | 0.001 |
| Any revascularization | 528 (10.3%) | 359 (7.2%) | 1.47 (1.28-1.68) | ＜0.001 | 1.41 (1.23-1.62) | ＜0.001 |
| Target vessel revascularization | 293 (5.7%) | 190 (3.8%) | 1.53 (1.27-1.84) | ＜0.001 | 1.45 (1.20-1.74) | ＜0.001 |
| Target lesion revascularization | 229 (4.4%) | 143 (2.8%) | 1.58 (1.28-1.95) | ＜0.001 | 1.50 (1.21-1.85) | ＜0.001 |
| Stroke | 101 (2.0%) | 65 (1.3%) | 1.51 (1.10-2.06) | ＜0.001 | 1.44 (1.05-1.98) | 0.024 |
| Any bleeding | 329 (6.4%) | 367 (7.3%) | 0.87 (0.75-1.01) | 0.070 | 0.88 (0.76-1.02) | 0.086 |
| Clinically relevant bleeding d | 130 (2.5%) | 148 (2.9%) | 0.85 (0.67-1.08) | 0.181 | 0.84 (0.66-1.06) | 0.143 |
Values are number of events (%). ＊ Variables entered into multivariable Cox regression models were as follows: for ischemic endpoints: age, sex, body mass index, hypertension, current smoking, left ventricular ejection fraction, peripheral artery disease, prior revascularization (percutaneous coronary intervention and/or coronary artery bypass graft), acute coronary syndrome, mean stent diameter, type of DES implanted, and DAPT duration (as a time-adjusted covariate); for bleeding endpoints: age, sex, body mass index, hypertension, prior major bleeding event, anemia, oral anticoagulation use at discharge, and DAPT duration (as a time-adjusted covariate).
CI = confidence interval; HR = hazard ratio; HIR = high ischemic risk; MI = myocardial infarction; ST = stent thrombosis
a Target vessel failure was defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization.
b Patient-oriented composite outcome was defined as the composite of all-cause death, any myocardial infarction, or any revascularization.
c Target lesion failure was defined as the composite of cardiac death, target vessel myocardial infarction, or target lesion revascularization.
d Clinically relevant bleeding was defined as BARC type 2, 3, or 5 bleeding.